Comparison Between Phenylephrine and Dopamine in Maintaining Cerebral Oxygen Saturation in Thoracic Surgery: A Randomized Controlled Trial

Ji Won Choi, MD, Hyun Joo Ahn, MD, PhD, Mkyung Yang, MD, PhD, Jie Ae Kim, MD, PhD, Sangmin M. Lee, MD, PhD, and Jin Hee Ahn, MD

Abstract: Fluid is usually restricted during thoracic surgery, and vasoactive agents are often administered to maintain blood pressure. One-lung ventilation (OLV) decreases arterial oxygenation; thus oxygen delivery to the brain can be decreased. In this study, we compared phenylephrine and dopamine with respect to maintaining cerebral oxygenation during OLV in major thoracic surgery.

Sixty-three patients undergoing lobectomies were randomly assigned to the dopamine (D) or phenylephrine (P) group. The patients’ mean arterial pressure was maintained within 20% of baseline by a continuous infusion of dopamine or phenylephrine. Maintenance fluid was kept at 5 mL/kg/h. The depth of anesthesia was maintained with desflurane 1 MAC and remifentanil infusion under bispectral index guidance. Regional cerebral oxygen saturation (rScO2) and hemodynamic variables were recorded using near-infrared spectroscopy and esophageal cardiac Doppler.

The rScO2 was higher in the D group than the P group during OLV (OLV 60 min: 71 ± 6% vs 63 ± 12%; P = 0.03). The number of patients whose rScO2 dropped more than 20% from baseline was 0 and 6 in the D and P groups, respectively (P = 0.02). The D group showed higher cardiac output, but lower mean arterial pressure than the P group (4.7 ± 1.0 vs 3.9 ± 1.2 L/min; 76.7 ± 8.1 vs 84.5 ± 7.5 mm Hg; P = 0.02, P = 0.02). Among the variables, age, hemoglobin concentration, and cardiac output were associated with rScO2 by correlation analysis.

Dopamine was superior to phenylephrine in maintaining cerebral oxygenation during OLV in thoracic surgery.

(Medicine 94(49):c2212)

INTRODUCTION

A restrictive fluid regimen has been recommended in thoracic surgery because acute lung injury (ALI) is known to correlate with the amount of fluid administration during operations. One study suggests that, for every 500 mL increase in perioperative fluids, there is an odds ratio (OR) of 1.17 for developing ALI after lung resection. Slinger suggested that fluid should be restricted just to the point of maintaining a urine output of 0.5 mL/kg/h and vasoactive agents may be used if tissue perfusion is inadequate. Therefore, restriction of fluid administration and treatment of hypotension, which is not caused by major hemorrhage, with vasoactive agents, could be a basic concept in thoracic anesthesia.

Patients undergoing lung resection surgery usually receive one-lung ventilation (OLV). During OLV, a significant decrease in cerebral oxygenation can occur. Because the goal of hemodynamic optimization is to improve oxygen delivery to major organs, understanding how the administration of vasoactive agents affects cerebral perfusion and oxygenation, the most important organ in the body, would be of major clinical relevance, especially during OLV.

However, there are no data comparing vasoactive drugs in terms of maintaining cerebral oxygenation during thoracic surgery. Therefore, we compared 2 commonly used agents, phenylephrine and dopamine, continuous infusion with respect to maintaining regional cerebral oxygen saturation (rScO2) during OLV in major thoracic surgery.

Our hypothesis is that dopamine continuous infusion provides higher rScO2 during OLV than phenylephrine continuous infusion.

The primary aim of our study was to investigate the effects of phenylephrine and dopamine continuous infusion on rScO2 during OLV. As secondary outcome, we identified the hemodynamic variables which are responsible for the changes in rScO2 in major thoracic surgery.
METHODS

This was a parallel-design, 1:1 allocation, randomized, double-blind (participants, assessors of outcomes) controlled study. The ClinicalTrials.gov ID is NCT02009007.

Study Population

After approval by the Institutional Review Board of Samsung Medical Center, Seoul, Republic of Korea, 63 patients undergoing elective thoracic surgery for lung cancer in a tertiary care academic center, from January 2013 to December 2013, were recruited, and written informed consent was obtained from each patient. Eligibility criteria were: age >18 years, elective lobectomy or bilobectomy, American Society of Anesthesiologists (ASA) physical status I–III, and presenting with at least a 20% decrease in mean arterial pressure (MAP) during anesthesia. Exclusion criteria were: forced expiratory volume in 1 second <60% of predicted values, cerebrovascular disease, poorly controlled hypertension (systolic arterial pressure ≥160 mm Hg), poorly controlled diabetes mellitus (blood glucose ≥200 mg/dL), diuretics or antidepressant use before operation, and renal insufficiency (creatinine >1.5 mg/dL). The patients were randomly assigned to the dopamine (D) or phenylephrine (P) groups using the computerized random number generator program (www.randomizer.org). An enclosed assignment in a sequentially numbered, opaque, sealed envelope was allocated to each patient. This envelope was opened only by 1 author (HJA) at the theatre, and the card inside determined whether the patient was in the D or P group. The anesthesiologists who maintained blood pressure within 20% of baseline with the allocated drug were neither involved in data collection nor in interpretation of test results. Patients were also blinded to the allocation group.

Anesthesia and Monitoring

After the patient’s arrival in the operating theatre, a BIS monitor (Aspect Medical System, Norwood, MA) and 2 near-infrared spectroscopy (NIRS) probes (INVOS 5100C: Somanetics Corp., Troy, MI), 1 on each side of the forehead, were placed, in addition to the other routine monitors. After inducing anesthesia with fentanyl (1.5–2 μg/kg), propofol (2–3 mg/kg), and rocuronium (0.8 mg/kg), all patients were intubated with a double lumen endotracheal tube (Mallinckrodt, Covidien, Mansfield, MA) and maintained with balanced anesthesia using desflurane 1MAC and remifentanil (0.05–0.2 μg/kg/min). The depth of anesthesia was maintained similarly between BIS 40 and 55 in both groups. The remifentanil infusion rate was based on the patient’s age, ASA physical status, and BIS monitoring. A radial arterial catheter and an esophageal Doppler probe (CardioQ, Deltex Medical, UK) were placed after tracheal intubation.

Baseline MAP was a value recorded when the patients arrived to the operating room and were stabilized for 10 minutes. The drug was started when the MAP decreased more than 20% of baseline after anesthesia. Dopamine was started at 5 μg/kg/min and phenylephrine at 1 μg/kg/min, and the infusion was adjusted for MAP to stay within 20% of baseline. SpO₂ was

FIGURE 1. Flow diagram of patient selection.
maintained above 94% by adjustment of positive end-expiratory pressure (PEEP) and FiO₂ during OLV.

The cerebral rsScO₂ was monitored by NIRS (INVOS 5100C: Somanetics Corp., Troy, MI) with optodes placed to the forehead above the frontal sinuses. INVOS 5100C employs a dual-detector system to subtract a shallow light path from a deep light path, allowing the derivation of the average oxyhemoglobin saturation in a volume of tissue about 2.5 to 3.0 cm below the skin. The device displays an approximation of venous-weighted hemoglobin saturation in tissue deep to the sensor. Mean values of right and left optodes were analyzed.

### TABLE 1. Patient Characteristics

|                        | Group D (n = 25) | Group P (n = 25) | P    |
|------------------------|-----------------|-----------------|------|
| Sex, male/female       | 20/5            | 18/7            | 0.74 |
| Age, y                 | 70.1 ± 4.1      | 71.1 ± 5.7      | 0.49 |
| Height, cm             | 161.9 ± 8.6     | 161.9 ± 7.8     | 0.99 |
| Weight, kg             | 63.4 ± 10.1     | 61.4 ± 8.9      | 0.46 |
| BMI, kg/m²             | 24.1 ± 2.9      | 23.5 ± 3.2      | 0.45 |
| ASA classification, I/II/III | 2/20/3      | 2/23/0          | 0.31 |
| Diabetes mellitus, Y/N | 6/19            | 2/23            | 0.25 |
| Hypertension, Y/N      | 18/7            | 14/11           | 0.38 |
| Angina, Y/N            | 1/24            | 3/22            | 0.61 |
| COPD, Y/N              | 9/16            | 7/18            | 0.76 |
| Idiopathic pulmonary fibrosis, Y/N | 1/24      | 0/25            | 1.00 |
| Preoperative CCRT, Y/N | 1/24            | 2/23            | 1.00 |
| Forced expiratory volume, L | 2.4 ± 0.6   | 2.3 ± 0.6       | 0.72 |
| Ejection fraction, %    | 64 ± 6          | 67 ± 9          | 0.31 |
| Creatinine, mg/dL       | 0.9 ± 0.3       | 0.9 ± 0.2       | 0.45 |
| Glomerular filtration rate, mL/min      | 81 ± 20       | 82 ± 19         | 0.87 |

Data are mean ± SD or number.

Group D, patients treated with dopamine; group P, patients treated with phenylephrine.

ASA = American Society of Anesthesiologists, BMI = body mass index, CCRT = concurrent chemoradiotherapy, COPD = chronic obstructive pulmonary disease, N = no, Y = yes.

### TABLE 2. Operative Data

|                        | Group D (n = 25) | Group P (n = 25) | P    |
|------------------------|-----------------|-----------------|------|
| Lobectomy/bilobectomy  | 23/2            | 21/4            | 0.67 |
| VATS/thoracotomy       | 10/15           | 10/15           | 1.00 |
| Surgeons, 1/2/3/4/5    | 8/3/11/2/1      | 9/5/5/5/1       | 0.98 |
| Amount of colloid, mL   | 72 ± 172        | 121 ± 205       | 0.36 |
| Amount of crystalloid, mL | 1300 ± 405     | 1184 ± 333      | 0.28 |
| Estimated blood loss, mL | 250 (150–300)  | 200 (150–300)   | 0.91 |
| pRBC use               | 1               | 0               | 0.33 |
| Total urine output, mL | 420 (282–720)   | 190 (90–340)    | <.001|
| Urine output, mL/kg/h  | 2.1 ± 1.1       | 1.0 ± 1.0       | <.001|
| One-lung ventilation time, min | 122 (92–148) | 116 (93–163)   | 0.89 |
| Operation time, min    | 163 (120–210)   | 150 (113–207)   | 0.51 |
| Anesthesia time, min   | 228 (185–267)   | 211 (177–265)   | 0.51 |
| Dopamine/phenylephrine, µg/kg/min* | 4.3 ± 1.9     | 0.8 ± 0.4       | 0.89 |
| Remifentanil, mg        | 0.8 ± 0.4       | 0.8 ± 0.4       | 0.89 |
| End-tidal desflurane concentration, vol%* | 5.1 ± 1.0   | 5.2 ± 1.2       | 0.38 |
| Temperature, °C        | 35.8 ± 0.4      | 35.8 ± 0.4      | 0.84 |
| Hb concentration, g/dL* | 12.9 ± 1.5     | 12.4 ± 1.4      | 0.31 |
| Bispectral index*       | 41 ± 7          | 43 ± 6          | 0.41 |
| Postoperative epidural analgesia, Y/N | 6/19         | 5/20            | 1.00 |

Data are mean ± SD or median (interquartile range) or number.

Group D, patients treated with dopamine; group P, patients treated with phenylephrine; surgeons, each surgeon was coded as numbers.

Temperature is measured from patient’s esophagus.

Hb = hemoglobin, pRBC = packed red blood cell, VATS = video-assisted thoracoscopic surgery, Y = yes N = no.

* Values are averages of 4 time points (15 min after induction, 30 and 60 min after OLV and 15 min after the restart of two-lung ventilation).
Cardiac output (CO) and stroke volume (SV) were monitored using an esophageal Doppler (CardioQ, Deltex Medical, UK). The esophageal Doppler measures blood flow velocity in the descending aorta. The aortic diameter is obtained from a built-in nomogram. SV is obtained by multiplying the blood flow distance and the cross-sectional area of the aorta.

Arterial blood gas was analyzed at baseline, 15 minutes after induction (TLVB), 30 and 60 minutes after OLV (OLV30, OLV60), and 15 minutes after the restart of two-lung ventilation (TLVA). All hemodynamic and rScO2 data were retrieved from the monitor after each case by the primary investigator who was not involved in anesthesia. The values of baseline, TLVB, OLV30, OLV60, and TLVA were recorded.

An intravenous infusion of lactated Ringer solution was maintained at 5 mL/kg/h throughout anesthesia. Blood loss was replaced by the same amount of hydroxyethyl starches. Packed red blood cell was transfused if the hemoglobin concentration fell below 8 g/dL. Pressure-controlled ventilation was used with a tidal volume of 6 mL/kg of predicted body weight and a ventilatory frequency of 8 to 12 bpm, with a target EtCO2 between 35 and 45 mm Hg. The arterial O2 saturation was monitored by a finger pulse oximeter (Nellcor, Covidien, Mansfield, MA).

Postoperative Complications and Intensive Care Unit (ICU) Stay

Postoperative complications within 48 hours, the duration of mechanical ventilation, and ICU stay were compared between the 2 groups. Acute kidney injury (AKI) was measured by acute kidney injury network (AKIN) score. Postoperative delirium was monitored by the confusion assessment method in intensive care unit (CAM-ICU). Trained ICU nurses who were unaware of the study allocation assessed delirium every hour until ICU discharge.

Statistical Analysis

Since no previous study exists, we referred a bolus study of similar vasoactives for sample size calculation, in which the mean difference of rSO2 was 10% between bolus phenylephrine and bolus ephedrine (P < 0.05).7 We regarded 15% as a clinically meaningful difference as a continuous infusion study. We conducted a pilot study to obtain standard deviations (SDs) of continuous infusions under OLV which were ±7% and ±9% in the D and P groups, respectively (n = 5, each group). We used 15% SDs for both groups as a more conservative approach. As a result, a sample size of 25 in each group was required with alpha level 0.05 and statistical power 80%. Considering a dropout rate of 20%, we chose a sample size of 30 per group. Sample size calculation was conducted by the software G*Power 3.1.9.2.

The mixed-effect model was used to conduct within-group comparison across different time points. Between-group comparison was done at each time point by Student t test or Mann–Whitney U test, as appropriate. Bonferroni correction was used to adjust multiple comparisons. Normality test was done by Shapiro–Wilk test. Relationships between independent variables and rScO2 were tested using Pearson correlation analysis.

Results presented as mean ± SD for data normally distributed, and median (interquartile range [IQR]) for data not normally distributed and a value of P value 0.05 was considered statistically significant. Data were analyzed by the software program SAS 9.4 (SAS institute, Inc., Cary, NC).

RESULTS

Three patients refused enrollment. Ten patients did not develop a lower than 20% decrease in MAP after anesthesia and were excluded from the study. Fifty patients were able to finish the study (group D, n = 25; or group P, n = 25; Fig. 1). Detailed patients characteristics and planned surgeries are described in Tables 1 and 2. There were no differences in demographic and operative data between the 2 groups except urine output. It was higher in the D group than in the P group during operation (420 [282–720] vs 190 [90–340] ml; P < 0.001). Amount of anesthetics, fluid, blood loss, and mean hemoglobin concentration were not different between the groups. One patient of group D received a pack of red blood cell. SpO2 was maintained above 94% during OLV in all patients. Mean doses of dopamine and phenylephrine during OLV were 4.3 ± 1.9 and 0.8 ± 0.4 µg/kg/min, respectively. The rScO2, CO, HR, and MAP just before the drug infusion were not different between the D and P groups (rSO2, 73 ± 6% vs 72 ± 7%; CO, 4.2 ± 1.0 vs 3.9 ± 0.8 L/min; HR, 71 ± 12 vs 71 ± 13 bpm; MAP, 63 ± 6 vs 63 ± 6 mm Hg).

The D group maintained higher rScO2 than the P group during OLV (OLV30, 73 ± 6% vs 69 ± 9%, P = 0.12; OLV60, 71 ± 6% vs 63 ± 12%, P = 0.03; OLVmean, 72 ± 6% vs 66 ± 10%, P = 0.01; Table 3). The trend of rSO2 over time was different between the groups (P = 0.03) and within group D (P = 0.01) and P (P < 0.01). The rSO2 of baseline was higher than the rSO2 of OLV60 (P < 0.001) and TLVA (P = 0.02). The rSO2 of OLV30 was higher than the rSO2 of OLV60 (P < 0.001). In group D, the rSO2 of OLV30 was higher than that of OLV60 (P = 0.03). In group P, the rSO2 of baseline, 

### TABLE 3. Regional Cerebral Oxygen Saturation (rScO2) During One-lung Ventilation

| Group | Data | Group | Data |
|-------|------|-------|------|
| **Baseline rScO2 (%)** | 73 ± 7 | **Baseline rScO2 (%)** | 71 ± 9 |
| Before infusion rScO2 (%) | 73 ± 6 | Before infusion rScO2 (%) | 72 ± 7 |
| OLVmean rScO2 (%) | 72 ± 6 | OLVmean rScO2 (%) | 66 ± 10* |
| OLV30 | 73 ± 6 | OLV30 | 69 ± 9 |
| OLV60 | 71 ± 6 | OLV60 | 63 ± 12* |
| **Decrease of rSO2 >20%, Y/N** | 0/25 (0) | **Decrease of rSO2 >20%, Y/N** | 6/19 (24)* |
| **The lowest rScO2 (%)** | 65 ± 6 | **The lowest rScO2 (%)** | 60 ± 10* |

* P < 0.05.

Data are mean ± standard deviation or n (%).

Group D, patients treated with dopamine; group P, patients treated with phenylephrine;
OLV30, 30 min after OLV; OLV60, 60 min after OLV. rScO2 = regional cerebral oxygen saturation.
TABLE 4. Hemodynamics and Blood Gas Analysis During One-lung Ventilation

|                     | Group D                       | Group P                      | P           |
|---------------------|-------------------------------|------------------------------|-------------|
|                     | Baseline            | OLV                               | Baseline | OLV       |                          |
| Heart rate, beats/min | 77 ± 12                      | 78 ± 12                         |            |           |                          |
| MAP, mm Hg          | 92 ± 11                      | 77 ± 8\(^*\)                    |            |           |                          |
| Cardiac output, L/min | 4.1 ± 0.8                   | 4.7 ± 1.0\(^1\)                |            |           |                          |
| Stroke volume, mL    | 58 ± 12                      | 63 ± 13                         |            |           |                          |
| FiO\(_2\)           | 0.7 ± 0.2                    | 0.8 ± 0.2\(^*\)                |            |           |                          |
| PaO\(_2\), mm Hg    | 318 ± 106                    | 179 ± 88\(^*\)                 |            |           |                          |
| PF ratio, mm Hg     | 482 ± 128                    | 237 ± 125\(^*\)                |            |           |                          |
| PaCO\(_2\), mm Hg   | 39 ± 5                       | 41 ± 4\(^1\)                    |            |           |                          |
| pH                  | 7.4 ± 0.1                    | 7.4 ± 0.1\(^1\)                |            |           |                          |
| Temperature, °C     | 35.8 ± 0.4                   | 35.7 ± 0.4                      |            |           |                          |
| Hb concentration, g/dL | 12.5 ± 1.6                  | 13.2 ± 1.6\(^*\)               |            |           |                          |

Data are mean ± SD.
Group D, patients treated with dopamine; group P, patients treated with phenylephrine.
Temperature is measured from patient’s esophagus.

Hb = hemoglobin, MAP = mean arterial pressure, OLV = one-lung ventilation, PF ratio = PaO\(_2\)/FiO\(_2\).
\(^1\)P < 0.05 versus baseline.
\(^*\)P < 0.05 versus between the 2 groups.

OLV30, and TLVA were higher than that of OLV60 (P < 0.01, P < 0.01, P = 0.03, respectively). The number of patients whose rScO\(_2\) dropped >20% from baseline was 0 and 6 (24%) patients in the D and P groups, respectively (P = 0.02). The lowest rScO\(_2\) was 65 ± 6% and 60 ± 10% in the D and P groups, respectively (P = 0.02; Table 3).

The D group showed a higher CO and a lower MAP than the P group (CO, 4.7 ± 1.0 vs 3.9 ± 1.2 L/min; MAP, 77 ± 8 vs 85 ± 8 mm Hg; P = 0.02, P = 0.02, respectively; Table 4, Figs. 2 and 3). The CO of OLV30, OLV60, and TLVA were higher than that of baseline in the D group (P = 0.01, P < 0.01, P < 0.01, respectively). The CO of OLV30 was higher than that of baseline in the P group (P = 0.04) (Fig. 2). The MAP of TLVB, OLV30, OLV60, and TLVA were lower than that of baseline in the D group (P < 0.001, all). The MAP of OLV30 was lower than that of baseline in the P group (P < 0.01) (Fig. 3).

Other variables, such as FiO\(_2\), PaO\(_2\), PaCO\(_2\), PaO\(_2\)/FiO\(_2\) (PF ratio), pH, temperature, and hemoglobin concentration, were not different between the groups.

Among variables, age, hemoglobin concentration, and CO were correlated with rScO\(_2\) (r = -0.37, 0.30, and 0.31; P = 0.01, 0.03, and 0.03, respectively) in the whole population. There was no correlation between rScO\(_2\) and other variables such as FiO\(_2\), PaO\(_2\), PaCO\(_2\), SpO\(_2\), PF ratio, pH, BIS, and OLV duration (Fig. 4) in the whole population.

FIGURE 2. Group means and standard deviation for cardiac output during operation. Changes were depicted from a baseline set at 100%. \(^1\)P < 0.05 between the 2 groups; \(^*\)P < 0.05 versus baseline of group D; \(^1\)P < 0.05 versus baseline of group P. Before infusion, just before the drug infusion; OLV30, 30 min after one-lung ventilation; OLV60, 60 min after one-lung ventilation; TLVA, 15 minutes after the restart of two-lung ventilation.

FIGURE 3. Group means and standard deviation for mean arterial pressure during operation. Changes were depicted from a baseline set at 100%. \(^1\)P < 0.05 between the 2 groups; \(^*\)P < 0.05 versus baseline of group D; \(^1\)P < 0.05 versus baseline of group P. Before infusion, just before the drug infusion; TLVB, 15 minutes after induction; OLV30, 30 min after one-lung ventilation; OLV60, 60 min after one-lung ventilation; TLVA, 15 minutes after the restart of two-lung ventilation.
There were no differences in the incidence of delirium (5 vs 6), AKI (2 vs 0), arrhythmia (4 vs 1), and mechanical ventilation (2 vs 3) between the D and P groups, respectively. There were no other serious respiratory or cardiac complications. Duration of ICU stay was similar (21.8 [18.3, 25.9] vs 21.7 [18.0, 24.6] h) between the D and P groups.

**DISCUSSION**

Our study showed that dopamine is superior to phenylephrine in maintaining cerebral oxygen saturation for patients receiving OLV during thoracic surgery. Age, hemoglobin concentration, and CO were correlated with rScO2.

The cerebral blood flow (CBF) decreases passively if the MAP falls below the lower limit of cerebral autoregulation, exposing the patient to possible cerebral hypoperfusion and ultimately, a reduction in rScO2. Immediate reductions in CBF and rScO2 have been reported when the MAP drops below 80 mm Hg.8,9 In our study, the MAP was higher in the P group than in the D group during OLV. However, the mean rScO2 was significantly lower in the P group than in the D group, and the difference of rScO2 between the 2 groups increased as OLV continued.

Only 3 studies7,10,11 have been published for the comparison of vasoactive drugs in relation to rScO2. In 1 study, patients received phenylephrine (100 µg intravenous [iv]) or ephedrine (10 mg iv) to restore MAP after anesthesia induction and rScO2 was monitored by INVOS cerebral oximeter. After administration of phenylephrine, MAP increased (51 to 81 mm Hg; P < 0.001), but rScO2 decreased by 14% (from 70% to 60%; P < 0.05). The administration of ephedrine led to a similar increase in MAP (53 to 79 mm Hg; P < 0.001) and preserved rScO2.7 Another study was a 2-treatment cross-over trial using Oxiplex TS cerebral oximeter; 1 bolus dose of phenylephrine (100–200 µg iv) and 1 bolus dose of ephedrine (5–20 mg iv). The rScO2 was significantly decreased after phenylephrine treatment (−3.2%; P < 0.01), but rScO2 was preserved after ephedrine treatment (+0.04%; P > 0.05).10 In a comparison study between phenylephrine and norepinephrine using FORE-SIGHT cerebral oximeter, phenylephrine and norepinephrine caused an equivalent increase in MAP [D = 13 [8–22] and D = 13 (9–19) mm Hg, respectively], and a similar decrease in cardiac index (both \( \Delta = -0.2 \pm 0.3 \text{ L/min/m}^2 \)) and rScO2 \( [\Delta = -4 \text{ \%} \text{ to } -2\%] \text{ and } \Delta = -4 [-5 \text{ to } -1\%], \text{ respectively} \).11

Phenylephrine and dopamine act in different mechanisms. Phenylephrine increases vasomotor tone and dopamine mainly increases myocardial contractility and heart rate (HR). Vasoactive amines do not cross the blood–brain barrier; therefore direct action of either phenylephrine or dopamine on cerebral vessels would be negligible.6 Therefore, we speculate that the administration of phenylephrine may have reduced CO. Reduced CO by phenylephrine has been documented in both animals and humans.12–14 In animal experiments, phenylephrine increased arterial pressure by 30%, but decreased CO by 30%, ejection fraction by 36%, and SV by 25%.14 The CO, SV, and HR decreased significantly after

**FIGURE 4.** Factors related to rScO2. Pearson correlation analysis showed cardiac output (CO) (A), age (B), and hemoglobin concentration (Hb) (C) were associated with rScO2. Hb = hemoglobin, rScO2 = regional cerebral oxygen saturation.
phenylephrine treatment in anesthesia-induced hypotensive patients, whereas ephedrine preserved CO and SV, and increased HR. Phenylephrine leads to increased vagal tone as demonstrated by slowed HR, and this can also result in decrease in CO. A significant linear relationship was shown between CO and the middle cerebral artery mean flow velocity.

Second, phenylephrine may constrict cerebral vessels indirectly through reflexive sympathetic nerve activation. Cerebral arteries are innervated by sympathetic nerve fibers abundantly, originating from the superior cervical ganglion. Activity of sympathetic nerves on cerebral vessels increases promptly after a phenylephrine-induced rapid increase in arterial pressure. In anesthetized patients, the phenylephrine bolus injection increased the MAP by 20% to 30% and caused a significant decrease in CBF. In the current study, age, hemoglobin (Hb) concentration, and CO, but not MAP, were identified as the variables associated with rScO2. Age and Hb concentration were not different between the D and P groups. Therefore, the distinctive effect of phenylephrine and dopamine on rScO2 may be mainly explained by their different impacts on CO. In the study by Meng et al, which compared phenylephrine and ephedrine boluses, CO was identified to have the most significant association with rScO2, and after taking CO into consideration, the other physiological variables were not significantly associated with rScO2. Therefore, it seems that higher CO is the key factor of higher rScO2 shown in the D group, compared with the P group. Other variables which can possibly influence rScO2 such as FiO2, SpO2, PaO2, PaCO2, pH, temperature, and depth of anesthesia, were controlled during OLV in this study, and there were no differences between the groups.

Low rScO2 measured by NIRS was associated with an increase of neurological damage, cognitive impairment, or postoperative complications during cardiac and thoracic surgery. However, there is no proven cut-off value of rScO2 below which cerebral ischemia may occur because there is substantial inter and intrapatient variability in rScO2. In our study, incidence of delirium defined by CAM-ICU was not different between the 2 groups, and there were no postoperative cerebrovascular incidents. Urine output was higher in the D group during operation, but the incidence of AKI was not different between the 2 groups. Incidence of new-onset arrhythmia or ICU stay was not different either. However, our study was not powered for complications. Further studies focused on clinical outcomes are required.

For limitation, this study was a monocentric approach of hemodynamic control to compare inotrope and vasopressor; therefore, it does not exactly reflect clinical practice which employs multimodal approach for hemodynamic control. Inotropes including dopamine have several side effects, such as increasing oxygen consumption of the heart muscle and leading to tachycardia, arrhythmia, and a higher risk for cardiac events. Therefore, risk–benefit balance should be taken into consideration, and individualized approach is required for each patient.

Secondly, we did not measure CBF directly, but rather oxygenation of the brain. Usually, changes in rScO2 parallel those in middle cerebral artery flow velocity (MCAV). An important role of CBF is to provide adequate oxygenation for the brain; therefore monitoring rScO2 instead of middle cerebral artery flow may be more relevant.

Thirdly, we measured CO using an esophageal Doppler. Vasoactive drugs could affect the diameter of the aorta, thus making esophageal Doppler measurement less accurate. However, esophageal Doppler is less invasive than pulmonary artery catheter and more accurate than most of the noninvasive CO monitors under the influence of vasopressors.

Forthly, phenylephrine may constrict scalp vessels and result in the reduction of rScO2. INVOS 5100C is supposed to measure rScO2 of 2.5 to 3.0 cm below the skin. However, the effect of scalp vessel constriction cannot be absolutely ruled out.

Final limitation is the lack of a control group. However, a control group that would not receive any treatment when blood pressure decreases was considered unethical. In previous reports, rScO2 dropped significantly when no drug intervention was given to treat hypotension during OLV.

In summary, cerebral oxygenation decreases after phenylephrine administration, but is maintained after dopamine continuous infusion in thoracic surgery patients undergoing OLV. The higher CO shown with the dopamine infusion may be beneficial in terms of maintaining cerebral oxygenation during OLV. We suggest that the increase in MAP is not a prerequisite to secure cerebral oxygenation, and CO should be increased to keep the optimum range of cerebral oxygenation.

ACKNOWLEDGMENTS

Authors’ contributions: HA contributed substantially to conception and design, acquisition of data, and analysis and interpretation of data. He drafted the article and revised it critically for important intellectual content and approved the final version to be published. JC contributed substantially to conception and design, acquisition of data, and analysis and interpretation of data. He drafted the article and revised it critically for important intellectual content, and approved the final version to be published. MY contributed substantially to acquisition of data, drafted the article, and revised it critically for important intellectual content, and approved the final version to be published. JK contributed substantially to acquisition of data, analysis and interpretation of data, drafted the article, and revised it critically for important intellectual content, and approved the final version to be published. SML contributed substantially to acquisition of data, drafted the article, and revised it critically for important intellectual content, and approved the final version to be published. IA contributed substantially to acquisition of data, analysis and interpretation of data, drafted the article, and revised it critically for important intellectual content, and approved the final version to be published.

REFERENCES

1. Licker M, de Perrot M, Spiliopoulos A, et al. Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesth Analg. 2003;97:1558–1565.
2. Alam N, Park BJ, Wilton A, et al. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg. 2007;84:1085–1091 discussion 1091.
3. Slinger PD. Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. J Cardiothorac Vasc Anesth. 1995;9:442–451.
4. Tobias JD, Johnson GA, Rehman S, et al. Cerebral oxygenation monitoring using near infrared spectroscopy during one-lung ventilation in adults. J Minim Access Surg. 2008;4:104–107.
5. Kazan R, Bracco D, Hemmerling TM. Reduced cerebral oxygen saturation measured by absolute cerebral oximetry during thoracic surgery correlates with postoperative complications. Br J Anaesth. 2009;103:811–816.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

www.md-journal.com
6. Hoffman GM, Ghanayem NS, Tweddell JS. Noninvasive assessment of cardiac output. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2005;11:21–26.

7. Nissen P, Brassard P, Jorgensen TB, et al. Phenytoin but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension. Neurocrit Care. 2010;12:17–23.

8. Madsen P, Pott F, Olsen SB, et al. Near-infrared spectrophotometry determined brain oxygenation during fainting. Acta Physiol Scand. 1998;162:501–507.

9. Madsen PL, Secher NH. Near-infrared oximetry of the brain. Prog Neurobiol. 1999;58:541–560.

10. Meng L, Cannesson M, Alexander BS, et al. Effect of phenylephrine and ephedrine bolus treatment on cerebral oxygenation in anaesthetized patients. Br J Anaesth. 2012;108:209–217.

11. Poterman M, Vos JJ, Vereecke HE, et al. Differential effects of phenylephrine and norepinephrine on peripheral tissue oxygenation during general anesthesia: a randomised controlled trial. Eur J Anaesthesiol. 2015;32:571–580.

12. Meng L, Gelb AW, Alexander BS, et al. Impact of phenylephrine administration on cerebral tissue oxygen saturation and blood volume is modulated by carbon dioxide in anaesthetized patients. Br J Anaesth. 2012;108:815–822.

13. Erkinaro T, Makikallio K, Acharya G, et al. Divergent effects of ephedrine and phenylephrine on cardiovascular hemodynamics of near-term fetal sheep exposed to hypoxemia and maternal hypotension. Acta Anaesthesiol. 2007;51:922–928.

14. Dunaway S, Yu Q, Larson DF. Effect of acute alpha adrenergic stimulation on cardiac function. Perfusion. 2007;22:289–292.

15. Ogoh S, Brothers RM, Barnes Q, et al. The effect of changes in cardiac output on middle cerebral artery mean blood velocity at rest and during exercise. J Physiol. 2005;569:697–704.

16. van Lieshout JJ, Pott F, Madsen PL, et al. Muscle tensing during standing: effects on cerebral tissue oxygenation and cerebral artery blood velocity. Stroke. 2001;32:1546–1551.

17. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol. 2006;100:1059–1064.

18. Edvinsson L, Owman C. Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res. 1974;35:835–849.

19. Arhab MA, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience. 1986;19:695–708.

20. Cassaglia PA, Griffiths RI, Walker AM. Sympathetic nerve activity in the superior cervical ganglia increases in response to imposed increases in arterial pressure. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1255–R1261.

21. Orihashi K, Sueda T, Okada K, et al. Near-infrared spectroscopy for monitoring cerebral ischemia during selective cerebral perfusion. Eur J Cardiothorac Surg. 2004;26:907–911.

22. Suehiro K, Okutai R. Duration of cerebral desaturation time during single-lung ventilation correlates with mini mental state examination score. J Anesth. 2011;25:345–349.

23. Jeong H, Jeong S, Lim HJ, et al. Cerebral oxygen saturation measured by near-infrared spectroscopy and jugular venous bulb oxygen saturation during arthroscopic shoulder surgery in beach chair position under sevoflurane-nitrous oxide or propofol-remifentanil anesthesia. Anesthesiology. 2012;116:1047–1056.

24. Argalious M, Motta P, Khandwala F, et al. Renal dose dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33:1327–1332.

25. Dellinger RP, Levy MM, Rhodes A, et al. International guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2013;39:165–288.

26. Skak C, Rasmussen A, Kirkegaard P, et al. Cerebral oxygen saturation and blood flow during liver transplantation. Anesth Analg. 1997;84:730–733.

27. Steiner LA, Pijster D, Strebel SP, et al. Near-infrared spectroscopy can monitor dynamic cerebral autoregulation in adults. Neurocrit Care. 2009;10:122–128.

28. Lee AJ, Cohn JH, Ranasinghe JS. Cardiac output assessed by invasive and minimally invasive techniques. Anesthesiol Res Pract. 2011;2011:475151.

29. Feldheiser A, Hunsicker O, Krebbel H, et al. Oesophageal Doppler and calibrated pulse contour analysis are not interchangeable within a goal-directed haemodynamic algorithm in major gynaecological surgery. Br J Anaesth. 2014;113:822–831.

30. Meng L, Tran NP, Alexander BS, et al. The impact of phenylephrine, ephedrine, and increased preload on third-generation Vigileo-FloTrac and esophageal Doppler cardiac output measurements. Anesth Analg. 2011;113:751–757.

31. Funk DJ, Moretti EW, Gan TJ. Minimally invasive cardiac output monitoring in the perioperative setting. Anesth Analg. 2009;108:887–897.

32. Davie SN, Grocott HP. Impact of extracranial contamination on regional cerebral oxygen saturation: a comparison of three cerebral oximetry technologies. Anesthesiology. 2012;116:834–840.